Soluble epoxide hydrolase inhibitors and heart failure.
Cardiovascular disease remains one of the leading causes of death in the Western societies. Heart failure (HF) is due primarily to progressive myocardial dysfunction accompanied by myocardial remodeling. Once HF develops, the condition is, in most cases, irreversible and is associated with a very high mortality rate. Soluble epoxide hydrolase (sEH) is an enzyme that catalyzes the hydrolysis of epoxyeicosatrienoic acids (EETs), which are lipid mediators derived from arachidonic acid through the cytochrome P450 epoxygenase pathway. EETs have been shown to have vasodilatory, antiinflammatory, and cardioprotective effects. When EETs are hydrolyzed by sEH to corresponding dihydroxyeicosatrienoic acids, their cardioprotective activities become less pronounced. In line with the recent genetic study that has identified sEH as a susceptibility gene for HF, the sEH enzyme has received considerable attention as an attractive therapeutic target for cardiovascular diseases. Indeed, sEH inhibition has been demonstrated to have antihypertensive and antiinflammatory actions, presumably due to the increased bioavailability of endogenous EETs and other epoxylipids, and several potent sEH inhibitors have been developed and tested in animal models of cardiovascular disease including hypertension, cardiac hypertrophy, and ischemia/reperfusion injury. sEH inhibitor treatment has been shown to effectively prevent pressure overload- and angiotensin II-induced cardiac hypertrophy and reverse the pre-established cardiac hypertrophy caused by chronic pressure overload. Application of sEH inhibitors in several cardiac ischemia/reperfusion injury models reduced infarct size and prevented the progressive cardiac remodeling. Moreover, the use of sEH inhibitors prevented the development of electrical remodeling and ventricular arrhythmias associated with cardiac hypertrophy and ischemia/reperfusion injury. The data published to date support the notion that sEH inhibitors may represent a promising therapeutic approach for combating detrimental cardiac remodeling and HF.
Qiu
Hong
H
Department of Internal Medicine, Division of Cardiovascular Medicine, University of California, Davis, CA, USA Department of Veterans Affairs, Northern California Health Care System Mather, CA, USA Department of Entomology and UC Davis Cancer Center, University of California, Davis, CA, USA.
Li
Ning
N
Liu
Jun-Yan
JY
Harris
Todd R
TR
Hammock
Bruce D
BD
Chiamvimonvat
Nipavan
N
D000818:Animals; D006332:Cardiomegaly / Q000517:prevention & control; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D015428:Myocardial Reperfusion Injury / Q000517:prevention & control; D020257:Ventricular Remodeling
D004791:Enzyme Inhibitors; D004851:Epoxide Hydrolases